- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Fall 2017
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Ferring Pharms. Inc. v. Novel Labs., Inc., 17-0894 (D. Del.) | July 5, 2017 | Hon. Richard G. Andrews | Prepopik® (sodium picosulfate / magnesium oxide / citric acid oral solution) |
8,450,338
8,481,083
9,669,110
|
| Sebela Int’l Ltd. V. Prinston Pharm. Inc., 17-4964 (D.N.J.) | July 6, 2017 | Hon. Claire C. Cecchi | Brisdelle® (paroxetine capsules) | 9,393,237 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc., 17-5005 (D.N.J.) | July 7, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Actelion Pharms. Ltd. v. Sun Pharm. Indus., Inc., 17-5015 (D.N.J.) | July 7, 2017 | Hon. Peter G. Sheridan | Veletri® (epoprostenol sodium for injection) | 8,598,227 |
| Duke University v. Sandoz Inc., 17-0528 (E.D. Tex.) | July 7, 2017 | Hon. Rodney Gilstrap | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Dr. Reddy’s Labs., Inc. v. Icos Corp., IPR2017-01757 (PTAB) | July 10, 2017 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
| KVK-Tech, Inc. v. Silvergate Pharms., Inc., PGR2017-00039 (PTAB) | July 10, 2017 | N/A | Qbrelis® (lisinopril oral solution) | 9,463,183 |
| Eli Lilly and Co. v. MacLeods Pharma USA, Inc., 17-5087 (D.N.J.) | July 12, 2017 | Hon. Michael A. Shipp | Cialis® (tadalafil tablets) | 6,943,166 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 17-5100 (D.N.J.) | July 12, 2017 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,629,965 |
| Argentum Pharms. LLC v. Icos Corp., IPR2017-01762 (PTAB) | July 12, 2017 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
| Gilead Sciences, Inc. v. Amneal Pharms. LLC, 17-0943 (D. Del.) | July 13, 2017 | Vacant Judgeship (2017) | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
|
| Par Pharm., Inc. v. Hospira, Inc., 17-0944 (D. Del.) | July 13, 2017 | Vacant Judgeship (2017) | Adrenalin® (epinephrine for injection) |
9,119,876
9,295,657
|
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharms., Inc., 17-5135 (D.N.J.) | July 13, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Galderma Labs., L.P. v. Perrigo UK Finco Ltd., 17-1860 (N.D. Tex.) | July 13, 2017 | Hon. Barbara M.G. Lynn | Soolantra® (ivermectin cream) |
8,815,816
9,089,587
9,233,117
9,233,118
|
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01767 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,254,278 |
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01768 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,095,559 |
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01769 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,326,966 |
| Biogen Int’l GMBH v. Zydus Pharms. (USA) Inc., 17-0954 (D. Del.) | July 14, 2017 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999
8,399,514
|
| Delcor Asset Corp. v. Taro Pharm. Indus., Ltd., 17-0970 (D. Del.) | July 17, 2017 | Hon. Richard G. Andrews | Evoclin® (clindamycin phosphate aerosol foam) |
7,141,237
7,374,747
|
| Delcor Asset Corp. v. Taro Pharm. Indus., Ltd., 17-5405 (S.D.N.Y.) | July 17, 2017 | Hon. Richard J. Sullivan | Evoclin® (clindamycin phosphate aerosol foam) |
7,141,237
7,374,747
|
| Epic Pharma, LLC v. Pfizer Inc., 17-0987 (D. Del.) | July 19, 2017 | Hon. Gregory M. Sleet | Zithromax® (azithromycin oral suspension) | 6,268,489 |
| Mitsubishi Tanabe Pharma Corp. v. Apotex, Inc., 17-5278 (D.N.J.) | July 19, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. Apotex, Inc., 17-0990 (D. Del.) | July 20, 2017 | Hon. Gregory M. Sleet | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. MSN Labs. Private Ltd., 17-5302 (D.N.J.) | July 20, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 17-5314 (D.N.J.) | July 20, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,189,740
8,404,717
9,056,120
|
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-5319 (D.N.J.) | July 20, 2017 | Hon. Michael A. Shipp | Invokana® (canagliflozin tablets) |
7,943,788
8,222,219
8,785,403
|
| Precision Dermatology, Inc. v. Lupin Ltd., 17-5333 (D.N.J.) | July 20, 2017 | Hon. Peter G. Sheridan | Locoid® (hydrocortisone butyrate lotion) | 7,981,877 |
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-1781 (D. Col.) | July 21, 2017 | Hon. R. Brooke Jackson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-1782 (D. Col.) | July 21, 2017 | Hon. Kristen L. Mix | Invokana® (canagliflozin tablets) | 7,943,788 |
| Mitsubishi Tanabe Pharma Corp. v. Teva Pharms. USA, Inc., 17-0998 (D. Del.) | July 21, 2017 | Hon. Gregory M. Sleet | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Bristol-Myers Squibb Co. v. Zydus Pharms. (USA) Inc., 17-5337 (D.N.J.) | July 21, 2017 | Hon. Peter G. Sheridan | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Merck Sharp & Dohme Corp. v. Apotex Inc., 17-5399 (D.N.J.) | July 24, 2017 | Hon. Peter G. Sheridan | Emend® (fosaprepitant dimeglumine for injection) | 5,691,336 |
| Takeda Pharms. U.S.A., Inc. v. Granules Pharms. Inc., 17-1019 (D. Del.) | July 25, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Takeda Pharms. U.S.A., Inc. v. Hetero Labs Ltd., 17-1020 (D. Del.) | July 25, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Bayer AG v. Mayne Pharma LLC, 17-1037 (D. Del.) | July 27, 2017 | Hon. Leonard P. Stark | Natazia® (estradiol valerate / dienogest tablets) | 8,071,577 |
| Gilead Sciences, Inc. v. Macleods Pharms., Ltd., 17-1039 (D. Del.) | July 27, 2017 | Vacant Judgeship (2017) | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
9,457,036
|
| Jazz Pharms., Inc. v. Ascent Pharms., Inc., 17-5487 (D.N.J.) | July 27, 2017 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
9,539,330
9,486,426
9,050,302
|
| Jazz Pharms., Inc. v. Ascent Pharms., Inc., 17-4439 (E.D.N.Y.) | July 27, 2017 | Hon. Pamela K. Chen | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
9,539,330
9,486,426
9,050,302
|
| Bayer Intellectual Property GMBH v. Lupin Ltd., 17-1047 (D. Del.) | July 28, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Allergan, Inc. v. Taro Pharms., Inc., 17-1048 (D. Del.) | July 28, 2017 | Vacant Judgeship (2017) | Aczone® (dapsone gel) | 9,517,219 |
| Endo Pharms. Inc. v. Lupin Atlantis Holdings SA, 17-0558 (E.D. Tex.) | July 28, 2017 | Hon. Rodney Gilstrap | Nascobal® (cyanocobalamin nasal spray) |
7,229,636
7,404,489
7,879,349
8,003,353
8,940,714
9,415,007
|
| AstraZeneca LP v. Invagen Pharms. Inc., 17-1073 (D. Del.) | Aug. 2, 2017 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
RE 46,276
7,250,419
7,265,124
|
| Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., 17-1078 (D. Del.) | Aug. 3, 2017 | Hon. Leonard P. Stark | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Horatio Washington Depot Technologies LLC v. Tolmar, Inc., 17-1086 (D. Del.) | Aug. 3, 2017 | Hon. Leonard P. Stark | Eligard® (leuprolide acetate for injection) |
5,932,547
6,124,261
6,235,712
|
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01910 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 6,774,122 |
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01912 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 8,466,139 |
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01913 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 8,329,680 |
| Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., 17-5955 (S.D.N.Y.) | Aug. 7, 2017 | Hon. William H. Pauley, III | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Horizon Therapeutics, LLC v. Lupin Ltd., 17-5900 (D.N.J.) | Aug. 8, 2017 | Hon. Kevin McNulty | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Horizon Therapeutics, LLC v. Par Pharm., Inc., 17-5901 (D.N.J.) | Aug. 8, 2017 | Hon. Kevin McNulty | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp., 17-5914 (D.N.J.) | Aug. 8, 2017 | Hon. Stanley R. Chesler | Lantus® (insulin glargine injection) |
7,476,652
7,713,930
|
| Bayer Intellectual Property GMBH v. Breckenridge Pharm., Inc., 17-1129 (D. Del.) | Aug. 11, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-1131 (D. Del.) | Aug. 11, 2017 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,669,023
9,669,024
9,675,610
9,675,611
9,682,077
|
| Aptalis Pharma US, Inc. v. Amneal Pharms. LLC, 17-1134 (D. Del.) | Aug. 11, 2017 | Hon. Leonard P. Stark | Canasa® (mesalamine rectal suppository) |
7,541,384
8,217,083
8,436,051
|
| Aptalis Pharma US, Inc. v. Amneal Pharms. LLC, 17-6090 (D.N.J.) | Aug. 11, 2017 | Hon. Claire C. Cecchi | Canasa® (mesalamine rectal suppository) |
7,541,384
8,217,083
8,436,051
|
| Eli Lilly and Co. v. Eagle Pharms., Inc., 17-2772 (S.D. Ind.) | Aug. 14, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| Celgene Corp. v. Cipla Ltd., 17-6163 (D.N.J.) | Aug. 15, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,465,800
7,855,217
7,968,569
8,530,498
8,648,095
9,101,621
9,101,622
|
| Actavis Elizabeth LLC v. Novartis A.G., IPR2017-01946 (PTAB) | Aug. 15, 2017 | N/A | Gilenya® (fingolimod capsules) | 9,187,405 |
| Cephalon, Inc. v. Slayback Pharma LLC, 17-1154 (D. Del.) | Aug. 16, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) | 8,791,270 |
| Sun Pharm. Indus., Ltd. v. Novartis A.G., IPR2017-01929 (PTAB) | Aug. 16, 2017 | N/A | Gilenya® (fingolimod capsules) | 9,187,405 |
| Onyx Therapeutics, Inc. v. Innopharma Inc., 17-1155 (D. Del.) | Aug. 17, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
|
| Kissei Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 17-1161 (D. Del.) | Aug. 18, 2017 | Hon. Leonard P. Stark | Rapaflo® (silodosin capsules) | 5,387,603 |
| Bayer Intellectual Property GMBH v. Torrent Pharms., Ltd., 17-1163 (D. Del.) | Aug. 18, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Teva Pharms. Int’l GMBH v. Apotex Inc., 17-1164 (D. Del.) | Aug. 18, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Eli Lilly and Co. v. Jiangsu Hansoh Pharm. Group Co., Ltd., 17-2864 (S.D. Ind.) | Aug. 21, 2017 | Hon. Richard L. Young | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Eli Lilly and Co. v. Apotex, Inc., 17-2865 (S.D. Ind.) | Aug. 21, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| Mitsubishi Tanabe Pharma Corp. v. Invagen Pharms., Inc., 17-6375 (D.N.J.) | Aug. 23, 2017 | Hon. Freda L. Wolfson | Invokamet® (metformin HCl tablets) | 7,943,788 |
| Abbvie Inc. v. Macleods Pharms., Ltd., 17-1199 (D. Del.) | Aug. 24, 2017 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
7,148,359
7,364,752
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| Teva Pharms. Int’l GMBH v. Fresenius Kabi USA, LLC, 17-1201 (D. Del.) | Aug. 24, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Onyx Therapeutics, Inc. v. Apotex Inc., 17-1202 (D. Del.) | Aug. 24, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Mylan Pharms. Inc. v. Pozen Inc., IPR2017-01995 (PTAB) | Aug. 24, 2017 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,220,698 |
| Forest Labs., LLC v. Aurobindo Pharma Ltd., 17-1210 (D. Del.) | Aug. 25, 2017 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) |
7,304,036
7,371,727
7,704,947
7,745,409
8,080,526
8,110,553
|
| BTG Int’l Ltd. v. Teva Pharms. USA, Inc., 17-6435 (D.N.J.) | Aug. 25, 2017 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Valeant Pharms. Int’l, Inc. v. Par Sterile Products, LLC, 17-6449 (D.N.J.) | Aug. 25, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
9,669,096
|
| Valeant Pharms. Int’l, Inc. v. Par Sterile Products, LLC, 17-6557 (S.D.N.Y.) | Aug. 28, 2017 | Hon. Paul A. Engelmayer | Relistor® (methylnaltrexone bromide for injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
9,669,096
|
| Onyx Therapeutics, Inc. v. Qilu Pharma, Inc., 17-1235 (D. Del.) | Aug. 30, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Alcon Research, Ltd. v. Cipla Ltd., 17-1244 (D. Del.) | Aug. 31, 2017 | Hon. Gregory M. Sleet | Pazeo® (olopatadine HCl ophthalmic solution) |
8,791,154
9,533,053
|
| Sanofi v. Aurobindo Pharma USA, Inc., 17-1247 (D. Del.) | Aug. 31, 2017 | Hon. Richard G. Andrews | Multaq® (dronedarone tablets) |
8,410,167
9,107,900
|
| Valeant Pharms. Int’l, Inc. v. Mylan Pharms., Inc., 17-6714 (D.N.J.) | Sept. 1, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) | 9,669,096 |
| Bristol-Myers Squibb Co. v. Emcure Pharms. Ltd., 17-6832 (D.N.J.) | Sept. 6, 2017 | Hon. Peter G. Sheridan | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Celgene Corp. v. Lotus Pharm Co., Ltd., 17-6842 (D.N.J.) | Sept. 6, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
5,635,517
6,315,720
6,561,977
6,755,784
7,189,740
7,465,800
7,855,217
7,968,569
8,315,886
8,404,717
8,530,498
8,626,531
8,648,095
9,056,120
9,101,621
9,101,622
|
| Janssen Products, L.P. v. Aurobindo Pharma Ltd., 17-6872 (D.N.J.) | Sept. 7, 2017 | Hon. William H. Walls | Prezista® (darunavir tablets) |
8,518,987
7,700,645
7,126,015
7,595,408
|
| Forest Labs., LLC v. Breckenridge Pharm., Inc., 17-1287 (D. Del.) | Sept. 8, 2017 | Hon. Mitchell S. Goldberg | Saphris® (asenapine maleate tablets) | 5,763,476 |
| Allergan, Inc. v. Aurobindo Pharma Ltd., 17-1290 (D. Del.) | Sept. 8, 2017 | Hon. Gregory M. Sleet | Lastacaft® (alcaftadine ophthalmic solution) | 8,664,215 |
| U.S. Dept. of Health and Human Services v. Aurobindo Pharma USA, Inc., 17-6911 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Prezista® (darunavir tablets) |
7,470,506
8,597,876
|
| Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 17-6921 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Entereg® (alvimopan capsules) |
6,469,030
8,946,262
|
| Eli Lilly and Co. v. Eagle Pharms., Inc., 17-1293 (D. Del.) | Sept. 11, 2017 | Vacant Judgeship (2017) | Alimta® (pemetrexed for injection) | 7,772,209 |
| Eli Lilly and Co. v. Glenmark Pharms. Ltd., 17-7024 (D.N.J.) | Sept. 12, 2017 | Hon. Katharine S. Hayden | Cialis® (tadalafil tablets) | 6,943,166 |
| Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-1303 (D. Del.) | Sept. 13, 2017 | Hon. Gregory M. Sleet | Subsys® (fentanyl sublingual spray) |
8,486,972
8,486,973
8,835,459
8,835,460
9,241,935
9,289,387
9,642,797
9,642,844
|
| Sandoz Inc. v. Duke University, 17-0823 (M.D.N.C.) | Sept. 14, 2017 | Hon. Catherine C. Eagles | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Indivior Inc. v. Alvogen Pine Brook, Inc., 17-7106 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Dr. Reddy’s Labs. S.A., 17-7111 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Teva Pharms. USA, Inc., 17-7115 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Par Pharm., Inc., 17-7020 (S.D.N.Y.) | Sept. 14, 2017 | Hon. Katherine B. Forrest | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Actavis Labs. UT, Inc., 17-1034 (D. Utah) | Sept. 14, 2017 | Hon. Dustin B. Pead | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Mylan Technologies, Inc., 17-0157 (N.D.W.V.) | Sept. 14, 2017 | Hon. Irene M. Keeley | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Teijin Ltd. v. Aurobindo Pharma Ltd., 17-1314 (D. Del.) | Sept. 15, 2017 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) |
6,255,474
7,361,676
8,372,872
9,107,912
|
| Forest Labs., LLC v. Prinston Pharm. Inc., 17-7191 (D.N.J.) | Sept. 18, 2017 | Hon. Brian R. Martinotti | Byvalson® (nebivolol / valsartan tablets) |
7,803,838
7,838,552
|
| Valeant Pharms. Int’l, Inc. v. Actavis LLC, 17-7206 (D.N.J.) | Sept. 18, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) |
9,669,096
9,492,445
|
| Purdue Pharma L.P. v. Par Pharm., Inc., 17-1334 (D. Del.) | Sept. 20, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) |
9,492,389
9,492,391
9,492,392
9,492,393
|
| Takeda Pharm. Co. Ltd. v. Indoco Remedies Ltd., 17-7301 (D.N.J.) | Sept. 20, 2017 | Hon. Stanley R. Chesler | Nesina® (alogliptin benzoate tablets) |
7,807,689
8,173,663
8,288,539
8,697,125
|
| Purdue Pharma L.P. v. Par Pharm., Inc., 17-1582 (D. Conn.) | Sept. 21, 2017 | Hon. Stefan R. Underhill | OxyContin® (oxycodone HCl extended-release tablets) |
9,492,389
9,492,391
9,492,392
9,492,393
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 17-11814 (D. Mass.) | Sept. 21, 2017 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone HCl extended-release tablets)
Xtampza® ER (oxycodone extended-release capsules)
|
9,693,961 |
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharms., Inc., 17-7342 (D.N.J.) | Sept. 21, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) | 8,513,202 |
| Shionogi Inc. v. Qingdao Baheal Pharm. Co. Ltd., 17-1347 (D. Del.) | Sept. 22, 2017 | Hon. Mitchell S. Goldberg | Fortamet® (metformin extended-release tablets) |
6,790,459
6,866,866
|
| Sucampo AG v. Teva Pharm. Indus. Ltd., 17-7451 (D.N.J.) | Sept. 25, 2017 | Hon. Peter G. Sheridan | Amitiza® (lubiprostone capsules) |
6,414,016
8,071,613
7,795,312
6,982,283
8,097,653
8,389,542
8,026,393
8,338,639
8,748,481
|
| Duke University v. Alembic Pharms., Ltd., 17-7453 (D.N.J.) | Sept. 25, 2017 | Hon. Brian R. Martinotti | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Biogen Int’l GMBH v. Teva Pharms. USA, Inc., 17-1361 (D. Del.) | Sept. 27, 2017 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376
7,320,999
|
| Wyeth LLC v. Sun Pharm. Indus. Ltd., 17-1362 (D. Del.) | Sept. 28, 2017 | Hon. Richard G. Andrews | Bosulif® (bosutinib tablets) |
7,417,148
7,919,625
|
GENERICally Speaking Fall 2017
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.